Steady As She Goes at Johnson & Johnson


For the past month, Johnson & Johnson's share price has followed the long-term trend in health care spending, moving steadily up and to the right. With shares now sitting near their 52-week and all-time highs, our health-care bureau chief Brenton Flynn was anxiously awaiting today's earnings report to take a pulse on the $200 billion health care giant.

Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.

The article Steady As She Goes at Johnson & Johnson originally appeared on

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.